

An Abbvie-MEH collaboration


## **Report 1: Real-world outcomes of a single intravitreal dexamethasone in DMO**

Livia Fäs, Amit Mishra, Veronika Lipkova, Robin Hamilton, Sobha Sivaprasad, Dun Jack Fu

Patients with DMO started on intravitreal dexamethasone (n = 418)

Treatment duration < 6 months (n = 50)  
Incomplete baseline values (n = 26)  
Incomplete follow-up (n = 71)  
Distinct eyes (n = 31)

Cohort taken forward for analysis (n = 240)




| (a)  |                   | Overall<br>(N=240) |
|--|-------------------|--------------------|
| <b>Gender</b>                                  |                   |                    |
|  | Male              | 145 (60.4%)        |
|  | Female            | 95 (39.6%)         |
| <b>Age at recruitment</b>                      |                   |                    |
|  | Mean (SD)         | 68.5 (9.88)        |
|  | Median [Min, Max] | 67.0 [29.0, 90.0]  |
| <b>Ethnicity</b>                               |                   |                    |
|  | Afro Caribbean    | 48 (20.0%)         |
|  | Caucasian         | 51 (21.3%)         |
|  | Chinese           | 1 (0.4%)           |
|  | Mixed             | 90 (37.5%)         |
|  | South East Asian  | 5 (2.1%)           |
|  | Unknown           | 45 (18.8%)         |
| <b>Multiple deprivation index<br/>(decile)</b> |                   |                    |
|  | 1                 | 6 (2.5%)           |
|  | 2                 | 35 (14.6%)         |
|  | 3                 | Overall<br>(N=240) |
|  | 4                 |                    |
|  | 5                 | 145 (60.4%)        |
|  | 6                 | 95 (39.6%)         |
|  | 7                 |                    |
|  | 8                 | 68.5 (9.88)        |
|  | 9                 | 67.0 [29.0, 90.0]  |
|  | 10                |                    |
|  | Missing           | 48 (20.0%)         |
| <b>IDAOPi</b>                                  |                   |                    |
|  | Mean (SD)         | 3.39 (2.33)        |
|  | Median [Min, Max] | 3.00 [1.00, 10.0]  |
|  | Missing           | 1 (0.4%)           |


| (b)  |                   | Overall<br>(N=240) |
|--|-------------------|--------------------|
| <b>Baseline Visual acuity (ETDRS letters)</b>                    |                   |                    |
|  | Mean (SD)         | 56.0 (16.3)        |
|  | Median [Min, Max] | 58.0 [0, 82.0]     |
| <b>Baseline VA greater than or equal to 70<br/>ETDRS letters</b> |                   |                    |
|  | <70               | 179 (74.6%)        |
|  | 70 or over        | 61 (25.4%)         |
| <b>Baseline Central subfoveal thickness (microns)</b>            |                   |                    |
|  | Mean (SD)         | 420 (142)          |
|  | Median [Min, Max] | 400 [160, 953]     |
| <b>Lens status</b>   |                   |                    |
|  | phakic            | 70 (29.2%)         |
|  | pseudophakic      | 169 (70.4%)        |
| <b>Baseline retinopathy</b>                                      |                   |                    |
|  | R0                | 1 (0.4%)           |
|  | R1                | 87 (36.3%)         |
|  | R2                | 71 (29.6%)         |
|  | R3A               | 5 (2.1%)           |
|  | R3S               | 75 (31.3%)         |
|  | U                 | 1 (0.4%)           |
| <b>Number of anti-VEGF injections prior</b>                      |                   |                    |
|  | Mean (SD)         | 12.8 (9.07)        |
|  | Median [Min, Max] | 10.0 [0, 50.0]     |
|  | Missing           | 69 (28.8%)         |
| <b>Number of anti-VEGF injections by category</b>                |                   |                    |
|  | < 6               | 43 (17.9%)         |
|  | > 18              | 42 (17.5%)         |
|  | 11-18             | 41 (17.1%)         |
|  | 6-10              | 45 (18.8%)         |
|  | Missing           | 69 (28.8%)         |

**Visual & anatomical outcomes resulting from initial  
intravitreal dexamethasone**

Visual acuity & Central sub-foveal thickness over time




Change from baseline over time



| (a)  | 0<br>(N=240)   | 1<br>(N=143)       | 2<br>(N=90)        | 3<br>(N=70)        | 4<br>(N=106)       | 5<br>(N=94)        | 6<br>(N=135)      |
|--|----------------|--------------------|--------------------|--------------------|--------------------|--------------------|-------------------|
| <b>Absolute visual acuity<br/>(ETDRS letters)</b>                  |                |                    |                    |                    |                    |                    |                   |
| Mean (SD)  | 55.9 (16.3)    | 58.7 (15.8)        | 56.8 (18.9)        | 57.8 (16.1)        | 55.4 (16.4)        | 56.2 (14.3)        | 57.0 (16.3)       |
| Median [Min, Max]  | 58.0 [0, 82.0] | 61.0 [0, 85.0]     | 61.0 [2.00, 85.0]  | 60.0 [2.00, 85.0]  | 60.0 [0, 78.0]     | 59.5 [5.00, 85.0]  | 60.0 [0, 85.0]    |
| <b>Change in visual acuity</b>                                     |                |                    |                    |                    |                    |                    |                   |
| Mean (SD)  | 0 (0)          | 2.67 (11.5)        | 4.06 (11.2)        | 1.81 (12.1)        | 1.28 (11.5)        | 1.16 (13.8)        | 1.22 (11.1)       |
| Median [Min, Max]  | 0 [0, 0]       | 2.00 [-40.0, 73.0] | 4.00 [-33.0, 28.0] | 1.50 [-33.0, 38.0] | 2.00 [-52.0, 58.0] | 1.00 [-50.0, 53.0] | 0 [-35.0, 30.0]   |
|  |                |                    |                    |                    |                    |                    |                   |
| (b)  | 0<br>(N=240)   | 1<br>(N=89)        | 2<br>(N=55)        | 3<br>(N=39)        | 4<br>(N=50)        | 5<br>(N=54)        | 6<br>(N=89)       |
| <b>Absolute central<br/>subfoveal thickness<br/>(mm3)</b>          |                |                    |                    |                    |                    |                    |                   |
| Mean (SD)  | 421 (142)      | 325 (102)          | 322 (97.6)         | 385 (132)          | 428 (152)          | 432 (138)          | 413 (147)         |
| Median [Min, Max]  | 400 [160, 953] | 312 [150, 640]     | 313 [152, 528]     | 386 [165, 741]     | 412 [172, 820]     | 422 [210, 800]     | 388 [150, 839]    |
| <b>Change in central<br/>subfoveal thickness<br/>from baseline</b> |                |                    |                    |                    |                    |                    |                   |
| Mean (SD)  | 0 (0)          | -114 (148)         | -142 (148)         | -65.7 (129)        | -51.1 (140)        | -35.2 (156)        | -24.5 (153)       |
| Median [Min, Max]  | 0 [0, 0]       | -71.0 [-641, 190]  | -107 [-801, 50.0]  | -47.6 [-383, 219]  | -32.3 [-403, 290]  | -24.0 [-574, 358]  | -13.0 [-651, 376] |


Follow-up of study eyes after starting intravitreal dexamethasone




**Using time-event analyses to interrogate visual and anatomical outcomes from a single intravitreal dexamethasone injection**



Time to VA increase of 5 or more ETDRS letters




Number at risk




| n   | events | median | 0.95LCL | 0.95UCL |
|-----|--------|--------|---------|---------|
| 225 | 130    | 3.63   | 2.33    | 4.43    |

Time to VA increase of 10 or more ETDRS letters




Number at risk




| n   | events | median | 0.95LCL | 0.95UCL |
|-----|--------|--------|---------|---------|
| 225 | 76     | 5.83   | 5.4     | NA      |

Duration of positive visual response (benefit of 5 letters or more)

Probability of sustaining positive visual response



Number at risk




n events median 0.95LCL 0.95UCL


130 119 4.07 3.27 5.3

Duration of positive visual response (benefit of 10 letters or more)

Probability of sustaining positive visual response



Number at risk




n events median 0.95LCL 0.95UCL


76 68 3.58 3.03 5.13



### Time to Ozurdex retreatment



### Number at risk



| n   | events | median | 0.95LCL | 0.95UCL |
|-----|--------|--------|---------|---------|
| 239 | 136    | 0.863  | 0.71    | 1.11    |